The Infona portal uses cookies, i.e. strings of text saved by a browser on the user's device. The portal can access those files and use them to remember the user's data, such as their chosen settings (screen view, interface language, etc.), or their login data. By using the Infona portal the user accepts automatic saving and using this information for portal operation purposes. More information on the subject can be found in the Privacy Policy and Terms of Service. By closing this window the user confirms that they have read the information on cookie usage, and they accept the privacy policy and the way cookies are used by the portal. You can change the cookie settings in your browser.
Although ovarian cancer is highly sensitive to chemotherapy, the majority of patients experience recurrence. As a result, it is rational to consider a maintenance strategy to improve overall survival (even if it does not increase the rate of “cure”) and delay the time to symptomatic disease progression. Although a phase III trial of single-agent paclitaxel delivered on a monthly schedule for 12 cycles...
Our objective was to find the maximum tolerated combination dose of daily oral lapatinib and weekly carboplatin (C) and paclitaxel (T; metronomic mCT). The secondary objectives included toxicity, safety, and efficacy of response to therapy in patients with relapsed ovarian and breast cancer previously treated with platinum chemotherapy. We conducted a phase I/II study of mCT plus lapatinib in 24...
Set the date range to filter the displayed results. You can set a starting date, ending date or both. You can enter the dates manually or choose them from the calendar.